Second phase II trial of rPA 102 [VaxGen].
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2014
At a glance
- Drugs RPA 102 (Primary)
- Indications Anthrax
- Focus Adverse reactions; Pharmacodynamics
- Sponsors VaxGen
- 14 Mar 2014 Status changed from planning to discontinued (vaccine development discontinued by VaxGen).
- 18 Sep 2010 Status changed from suspended to planning, according to an Emergent BioSolutions media release.
- 15 Jan 2007 Status change